LIVTENCITY▼® (maribavir) overview

• Dr Mark Harber (Consultant Nephrologist with Special Interest in Transplantation, Royal Free Hospital)
• Prof Karl Peggs (Professor of Transplant Science and Cancer Immunotherapy, University College London Hospitals)
• Dr Adnan Sharif (Consultant Nephrologist with Special Interest in Transplantation, University Hospitals Birmingham)

Book a meeting

Click this link to discuss the information on this page further with a Takeda representative.

LIVTENCITY: Approved in the UK for post-transplant adult patients with refractory CMV infection and/or disease.¹

CMV infection during post-transplant recovery puts patients at risk of graft rejection, increased hospitalisations, opportunistic infections, and mortality^2–6. Furthermore, management of persistent CMV infection can lead to resistance, graft rejection, neutropenia, and nephrotoxicity, while rates of drug resistance vary and can occur in up to 8% of HSCT recipients and in up to 31% of SOT recipients^2,7–9.

LIVTENCITY is the first and only therapy indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT)^1,5.

LIVTENCITY: REDEFINING POST-TRANSPLANT TREATMENT FOR REFRACTORY CMV INFECTION¹

• OFFERS A TREATMENT OPTION FOR POST-TRANSPLANT ADULT PATIENTS WHO BECOME REFRACTORY TO ANTI-CMV THERAPIES
• TWICE-DAILY, ORAL ADMINISTRATION, WITH OR WITHOUT FOOD¹
• MULTIMODAL MECHANISM OF ACTION THAT INHIBITS THE CMV-SPECIFIC UL97 PROTEIN KINASE^1,7,10

The Phase 3 SOLSTICE study

A summary of the efficacy outcomes and safety profile for LIVTENCITY in the Phase 3 SOLSTICE study can be found in the LIVTENCITY digital key facts booklet

References:

1. LIVTENCITY UK Summaries of Product Characteristics [GB & NI].
2. Felipe CR, et al. J Bras Nefrol. 2017;39:413–23.
3. Azevedo LS, et al. Clinics (Sau Paulo). 2015;70:515–23.
4. Peffault De Latour R, et al. J Med Virol. 2020;92:3665–73.
5. Henderson R, et al. Transp! Infect Dis. 2001;3(suppl. 2):57–9.
6. Schelfhout J, et al. Curr Med Res Opin. 2020;36:43–50.
7. Kotton CN, et al. Transplantation. 2018;102:900–31.
8. Maffini E, et al. Expert Rev Hematol. 2016;9:588–96.
9. Razonable RR, et al. Am J Transplant. 2013;13(suppl. 4):93–106.
10. Avery RK, et al. Clin Infect Dis 2022;75(4):690–701.